ES2061055T5 - Vacunas y vectores de principios activos fluidos que contienen un aceite metabolizante. - Google Patents

Vacunas y vectores de principios activos fluidos que contienen un aceite metabolizante.

Info

Publication number
ES2061055T5
ES2061055T5 ES90910773T ES90910773T ES2061055T5 ES 2061055 T5 ES2061055 T5 ES 2061055T5 ES 90910773 T ES90910773 T ES 90910773T ES 90910773 T ES90910773 T ES 90910773T ES 2061055 T5 ES2061055 T5 ES 2061055T5
Authority
ES
Spain
Prior art keywords
pct
active principles
metabolizing
vaccines
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90910773T
Other languages
English (en)
Other versions
ES2061055T3 (es
Inventor
Bernard Brancq
Gerard Trouve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9383410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061055(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Publication of ES2061055T3 publication Critical patent/ES2061055T3/es
Application granted granted Critical
Publication of ES2061055T5 publication Critical patent/ES2061055T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA EMULSION INYECTABLE UTILIZABLECOMO VACUNA O VECTOR DE PRINCIPIO ACTIVO QUE TIENE UNA FASE CONTINUA ACEITOSA QUE PRESENTA UNA BUENA TOLERANCIA EN CONDICIONES NORMALES DE INYECCION A UN HOMBRE O A UN ANIMAL, CARACTERIZADA POR: UNA VISCOSIDAD INFERIOR A 800 MLAS A 20 C Y COMPUESTA POR AL MENOS: 20 A 90% DE UN ADYUVANTE ACEITOSO LIQUIDO A 4 C QUE CONTIENE POR LO MENOS UNO O VARIOS EMULGENTES, APROPIADOS Y FARMACEUTICAMENTE ACEPTABLES, UNA MEZCLA EN CUALQUIER PROPORCION DE UNO O VARIOS ACEITES METABOLIZABLES CON UNO O VARIOS ACEITES NO METABOLIZABLES, 10 A 80% DE UNA FASE HIDROFILA QUE CONTIENE LOS PRINCIPIOS ACTIVOS O ANTIGENOS.
ES90910773T 1989-07-03 1990-06-29 Vacunas y vectores de principios activos fluidos que contienen un aceite metabolizante. Expired - Lifetime ES2061055T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8908918A FR2649013B1 (fr) 1989-07-03 1989-07-03 Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable

Publications (2)

Publication Number Publication Date
ES2061055T3 ES2061055T3 (es) 1994-12-01
ES2061055T5 true ES2061055T5 (es) 1998-03-01

Family

ID=9383410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90910773T Expired - Lifetime ES2061055T5 (es) 1989-07-03 1990-06-29 Vacunas y vectores de principios activos fluidos que contienen un aceite metabolizante.

Country Status (12)

Country Link
US (1) US5422109A (es)
EP (1) EP0480982B2 (es)
JP (1) JP3007142B2 (es)
AT (1) ATE96038T1 (es)
AU (1) AU655155B2 (es)
BR (1) BR9007502A (es)
DE (1) DE69004095T3 (es)
DK (1) DK0480982T3 (es)
ES (1) ES2061055T5 (es)
FR (1) FR2649013B1 (es)
NZ (1) NZ234337A (es)
WO (1) WO1991000107A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
CA2085827C (en) * 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
EP0662839A4 (en) * 1992-09-30 1995-09-06 Univ Ohio State Res Found ANTIGENIC VACCINES AND CONJUGATES.
FR2700957B1 (fr) * 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
FR2702374B1 (fr) * 1993-03-08 1995-04-14 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US5690942A (en) † 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
DE69636889T2 (de) * 1995-11-30 2007-12-06 Nof Corp. Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
GB9626865D0 (en) * 1996-12-24 1997-02-12 Cyanamid Websters Pty Limited Veterinary vaccines
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6524592B2 (en) * 1997-10-17 2003-02-25 American Home Products Corporation Veterinary vaccines
WO1999056776A2 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
FR2800280B1 (fr) 1999-10-29 2003-09-19 Seppic Sa Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite
JP2001131087A (ja) * 1999-11-05 2001-05-15 Chemo Sero Therapeut Res Inst オイルアジュバントワクチン
AU770475B2 (en) * 1999-12-23 2004-02-19 Aphton Corporation A stable immunogenic composition for frozen storage
FR2809961B1 (fr) * 2000-06-09 2004-12-03 Seppic Sa Utilisation d'ethers de sucres, comme adjuvants d'immunite dans les compositions vaccinales, compositions therapeutiques les renfermant et leur utilisation comme vaccins
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
ATE317267T1 (de) * 2000-11-07 2006-02-15 Immunovaccine Technologies Inc Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
DE10113284A1 (de) * 2001-03-16 2002-10-02 Heinrich Exner Adjuvans-Emulsion und Verfahren zu deren Verwendung
FR2823119B1 (fr) * 2001-04-05 2004-02-20 Seppic Sa Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
TWI494125B (zh) * 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
FR2956403B1 (fr) 2010-02-17 2014-10-17 Afssa Antigenes polypeptidiques de trichinella, et leurs applications
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
BR112014007927B1 (pt) 2011-10-06 2021-04-13 Immunovaccine Technologies Inc Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
EP2877208B1 (en) 2012-07-24 2021-05-12 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
FR3011850B1 (fr) 2013-10-15 2018-04-06 Cfl Biotech Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
PT3089754T (pt) 2013-12-31 2021-07-23 Infectious Disease Res Inst Formulações de vacina de dose única
CN105960241A (zh) 2014-01-21 2016-09-21 免疫设计公司 用于治疗过敏性病症的组合物
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
GB201506948D0 (en) * 2015-04-23 2015-06-10 Croda Int Plc Emulsions for injectable formulations
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
US3983228A (en) * 1973-08-28 1976-09-28 Merck & Co., Inc. Water-in-oil adjuvant composition
US4069313A (en) * 1974-11-19 1978-01-17 Merck & Co., Inc. Water-in-oil adjuvant composition
FR2342073A1 (fr) * 1976-02-27 1977-09-23 Merieux Inst Nouveau vaccin antivariolique sous forme de pate et son dispositif d'application
FR2501526A1 (fr) * 1981-03-13 1982-09-17 Montagne Noire Produits Chimiq Nouveaux emulsionnants et leur application pour la production de vaccins
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines

Also Published As

Publication number Publication date
DK0480982T3 (da) 1994-03-14
AU5963090A (en) 1991-01-17
EP0480982A1 (fr) 1992-04-22
JP3007142B2 (ja) 2000-02-07
FR2649013A1 (fr) 1991-01-04
DE69004095D1 (de) 1993-11-25
US5422109A (en) 1995-06-06
NZ234337A (en) 1992-12-23
DE69004095T3 (de) 1998-03-05
ES2061055T3 (es) 1994-12-01
DE69004095T2 (de) 1994-02-17
EP0480982B2 (fr) 1997-11-12
JPH04506521A (ja) 1992-11-12
AU655155B2 (en) 1994-12-08
EP0480982B1 (fr) 1993-10-20
ATE96038T1 (de) 1993-11-15
FR2649013B1 (fr) 1991-10-25
BR9007502A (pt) 1992-06-23
WO1991000107A1 (fr) 1991-01-10

Similar Documents

Publication Publication Date Title
ES2061055T5 (es) Vacunas y vectores de principios activos fluidos que contienen un aceite metabolizante.
DE69412391T2 (de) Flüssige Wasser in Oel Impfemulsion enthaltend ein metabolierbares Oel
BR9509897A (pt) Composição de liberação controlada para um material biologicamente ativo uso da mesma processo para preparação de uma composição de liberação controlada e para administração a mamíferos especialmente ao homem de um material biologicamante ativo e composição para uso como uma composição medicinal nasal
ES2102157T3 (es) Emulsion agua en aceite para uso cosmetico o farmaceutico.
ATE108327T1 (de) Hilfsmittelformulierung die eine emulsion mit submikronischen oeltropfen enthält.
ATE118177T1 (de) Emulsion.
ES2086931T5 (es) Emulsion agua en aceite estable en el curso del tiempo con alto contenido de silicona.
JPS6479104A (en) Water-in-oil type emulsified cosmetic in solid state
GB2273657B (en) Preparation of solid microspheres or air-filled microcapsules
FR2649012B1 (fr) Emulsions multiphasiques injectables
ES2196229T3 (es) Composicion de aceite de utilizacion general.
KR870004699A (ko) 피부를 촉촉하게 하는 미세유화액 조성물
OA09800A (en) Vaccine compositions containing liposomes.
DE69425552D1 (de) Emulsion auf der basis von 1-alpha,24-dihydroxy-vitamin d3
BR9406228A (pt) Agente de contraste de ultra-som e processos para a preparação do mesmo e para a geração de imagens melhoradas de um corpo de animal humano ou n o-humano
ES2025064B3 (es) Mezclas preservadoras.
KR910007520A (ko) 안정성이 개선된 트리티노인 유화크림 제제
KR910002470A (ko) 혈관 x선 촬영 보조제
WO2000037045B1 (en) Stabilized water-in-oil-in-water antigen delivery system
ATE87821T1 (de) Kosmetische zusammensetzung.
FR2347924A1 (fr) Composition presentant de meilleures caracteristiques d'injectabilite
KR970010714A (ko) 유중수형 유제 폭약용 유화제 및 그의 제조 방법
JPS56128705A (en) Acaricidal composition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480982

Country of ref document: ES